LEADER 01890oam  2200481   450 
001 9910716543703321
005 20210630085632.0
024 8 $a40-555
035   $a(CKB)5470000002522719
035   $a(OCoLC)1257552450
035   $a(EXLCZ)995470000002522719
100   $a20210625d2021      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aImproving drug pricing transparency and lowering prices for American consumers $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Sixteenth Congress, first session, May 21, 2019
210  1$aWashington :$cU.S. Government Publishing Office,$d2021.
215   $a1 online resource (vi, 187 pages) $ccolor illustrations
300   $aAccess ID (govinfo): CHRG-116hhrg40555.
300   $a"Serial no. 116-37."
320   $aIncludes bibliographical references.
517   $aImproving drug pricing transparency and lowering prices for American consumers 
606   $aDrugs$xPrices$zUnited States
606   $aPharmaceutical industry$zUnited States
606   $aPrescription pricing$zUnited States
606   $aPrescription pricing$xLaw and legislation$zUnited States
606   $aInsurance premiums$xLaw and legislation$zUnited States
608   $aLegislative hearings.$2lcgft
615  0$aDrugs$xPrices
615  0$aPharmaceutical industry
615  0$aPrescription pricing
615  0$aPrescription pricing$xLaw and legislation
615  0$aInsurance premiums$xLaw and legislation
801  0$bGPO
801  1$bGPO
801  2$bOCLCO
801  2$bGPO
906   $aBOOK
912   $a9910716543703321
996   $aImproving drug pricing transparency and lowering prices for American consumers$93440425
997   $aUNINA